These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3410777)

  • 1. Use of a narcotic antagonist (nalmefene) to suppress self-mutilative behavior in a stallion.
    Dodman NH; Shuster L; Court MH; Patel J
    J Am Vet Med Assoc; 1988 Jun; 192(11):1585-6. PubMed ID: 3410777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats.
    June HL; Grey C; Warren-Reese C; Durr LF; Ricks-Cord A; Johnson A; McCane S; Williams LS; Mason D; Cummings R; Lawrence A
    Alcohol Clin Exp Res; 1998 Dec; 22(9):2174-85. PubMed ID: 9884166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of narcotic antagonists to modify stereotypic self-licking, self-chewing, and scratching behavior in dogs.
    Dodman NH; Shuster L; White SD; Court MH; Parker D; Dixon R
    J Am Vet Med Assoc; 1988 Oct; 193(7):815-9. PubMed ID: 3192459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation into the use of narcotic antagonists in the treatment of a stereotypic behavior pattern (crib-biting) in the horse.
    Dodman NH; Shuster L; Court MH; Dixon R
    Am J Vet Res; 1987 Feb; 48(2):311-9. PubMed ID: 3826875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonpharmacologic management of stereotypic self-mutilative behavior in a stallion.
    McClure SR; Chaffin MK; Beaver BV
    J Am Vet Med Assoc; 1992 Jun; 200(12):1975-7. PubMed ID: 1639708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nalmefene for elective reversal of procedural sedation in children.
    Chumpa A; Kaplan RL; Burns MM; Shannon MW
    Am J Emerg Med; 2001 Nov; 19(7):545-8. PubMed ID: 11698998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of obsessive-compulsive cutting behavior with naltrexone.
    Bystritsky A; Strausser BP
    J Clin Psychiatry; 1996 Sep; 57(9):423-4. PubMed ID: 9746454
    [No Abstract]   [Full Text] [Related]  

  • 8. Behavioral effects of 6-methylene naltrexone (nalmefene) in rhesus monkeys.
    France CP; Gerak LR
    J Pharmacol Exp Ther; 1994 Sep; 270(3):992-9. PubMed ID: 7932212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid antagonists in the treatment of impulse-control disorders.
    Kim SW
    J Clin Psychiatry; 1998 Apr; 59(4):159-64. PubMed ID: 9590665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis.
    Bergasa NV; Schmitt JM; Talbot TL; Alling DW; Swain MG; Turner ML; Jenkins JB; Jones EA
    Hepatology; 1998 Mar; 27(3):679-84. PubMed ID: 9500694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nalmefene in the treatment of interstitial cystitis.
    Stone NN
    Urol Clin North Am; 1994 Feb; 21(1):101-6. PubMed ID: 8284832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implantable technology for long-term delivery of nalmefene for treatment of alcoholism.
    Costantini LC; Kleppner SR; McDonough J; Azar MR; Patel R
    Int J Pharm; 2004 Sep; 283(1-2):35-44. PubMed ID: 15363499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naltrexone decreases self-injurious behavior.
    Herman BH; Hammock MK; Arthur-Smith A; Egan J; Chatoor I; Werner A; Zelnik N
    Ann Neurol; 1987 Oct; 22(4):550-2. PubMed ID: 3481242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duration of opioid antagonism by nalmefene and naloxone in the dog. A nonparametric pharmacodynamic comparison based on generalized cross-validated spline estimation.
    Wilhelm JA; Veng-Pedersen P; Zakszewski TB; Osifchin E; Waters SJ
    Int J Clin Pharmacol Ther; 1995 Oct; 33(10):540-5. PubMed ID: 8574503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical review of self-mutilation in horses.
    McDonnell SM
    Anim Reprod Sci; 2008 Sep; 107(3-4):219-28. PubMed ID: 18541393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study.
    Karhuvaara S; Simojoki K; Virta A; Rosberg M; Löyttyniemi E; Nurminen T; Kallio A; Mäkelä R
    Alcohol Clin Exp Res; 2007 Jul; 31(7):1179-87. PubMed ID: 17451401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of nalmefene on side effects due to intrathecal morphine at cesarean section.
    Pellegrini JE; Bailey SL; Graves J; Paice JA; Shott S; Faut-Callahan M
    AANA J; 2001 Jun; 69(3):199-205. PubMed ID: 11759562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of nalmefene for intrathecal opioid-associated nausea in postpartum patients.
    Ward RC; Lawrence RL; Hawkins RJ; DiChiara SE; Biegner AR; Vacchiano CA
    AANA J; 2002 Feb; 70(1):57-60. PubMed ID: 11887546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A preliminary trial of nalmefene for the treatment of emotional numbing in combat veterans with post-traumatic stress disorder.
    Glover H
    Isr J Psychiatry Relat Sci; 1993; 30(4):255-63. PubMed ID: 8163362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of borderline personality disorder with opioid antagonists: buprenorphine, nalmefene, naloxone and naltrexone in the treatment of dissociative symptoms, self-mutilation and suicidal behavior].
    García MC
    Vertex; 2020 Apr; XXX(148):1-10. PubMed ID: 33890928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.